866-997-4948(US-Canada Toll Free)

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 87 Pages

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2016, provides in depth analysis on Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Overview 8
Therapeutics Development 9
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Stage of Development 9
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Therapy Area 10
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Indication 11
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Companies 15
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Products under Development by Universities/Institutes 18
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development 27
Bayer AG 27
Boehringer Ingelheim GmbH 28
Ironwood Pharmaceuticals Inc 29
NicOx SA 30
SynZyme Technologies LLC 31
Topadur Pharma AG 32
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles 33
A-8R - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
BAY sGCact - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
BAY-1636183 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
BI-703704 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
hydroxyurea - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
IW-1701 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
IW-1973 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
IWP-953 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
naproxcinod - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
NCX-1021 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
NCX-1653 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
NCX-250 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
NCX-422 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
NCX-429 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
NCX-434 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
NCX-466 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
NCX-470 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
NCX-667 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
nitric oxide - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Q-201 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
riociguat - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecule to Activate soluble guanylate cyclase for Hypertension and Parenchymal Hemorrhage - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Small Molecule to Activate Soluble Guanylate Cyclase for Oncology - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
TOPN-53 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
Vacno - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
vericiguat - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Projects 67
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products 73
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Featured News & Press Releases 74
Oct 18, 2016: Bayer to Present Data in Pulmonary Arterial Hypertension at the 2016 Annual Meeting of the American College of Chest Physicians 74
Sep 28, 2016: Pivotal Phase III Study Started With Vericiguat in Patients With Chronic Heart Failure 74
Sep 16, 2016: Withdrawal of the marketing authorisation application for Adempas (riociguat) 75
Jun 24, 2016: Adempas not for use in patients with pulmonary hypertension caused by idiopathic interstitial pneumonia 77
May 13, 2016: Bayer to Present Pulmonary Hypertension Data at American Thoracic Society 2016 International Conference 78
May 12, 2016: Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias 80
Mar 30, 2016: Ironwood Pharmaceuticals to Present Clinical Data on sGC Stimulator IW-1973 at Upcoming Scientific Conferences 80
Mar 30, 2016: Ironwood Pharmaceuticals to Present Clinical Data on sGC Stimulator IWP-953 at Upcoming Scientific Conferences 81
Feb 18, 2016: Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701 81
Nov 06, 2015: Latest Clinical Data of Vericiguat To Be Presented at Late-Breaking-Clinical-Trial Session at AHA 82
Nov 03, 2015: Ironwood Pharmaceuticals Initiates Clinical Study of Soluble Guanylate Cyclase Stimulator IW-1973 83
Nov 03, 2015: Ironwood Pharmaceuticals Initiates Clinical Study of Soluble Guanylate Cyclase Stimulator IW-1701 83
Oct 22, 2015: Bayer to Present Pulmonary Arterial Hypertension Data at American College of Chest Physicians Annual Meeting 84
Oct 07, 2015: Bayer to Evaluate Riociguat in Children Suffering from Pulmonary Arterial Hypertension 85
Jul 22, 2015: Ironwood Progresses sGC Stimulator Platform with Positive Top-Line Phase I Data on IW-1973 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87

List of Tables
Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Pipeline by Bayer AG, H2 2016 27
Pipeline by Boehringer Ingelheim GmbH, H2 2016 28
Pipeline by Ironwood Pharmaceuticals Inc, H2 2016 29
Pipeline by NicOx SA, H2 2016 30
Pipeline by SynZyme Technologies LLC, H2 2016 31
Pipeline by Topadur Pharma AG, H2 2016 32
Dormant Projects, H2 2016 67
Dormant Projects (Contd..1), H2 2016 68
Dormant Projects (Contd..2), H2 2016 69
Dormant Projects (Contd..3), H2 2016 70
Dormant Projects (Contd..4), H2 2016 71
Dormant Projects (Contd..5), H2 2016 72
Discontinued Products, H2 2016 73

List of Figures
Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Top 10 Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Mechanism of Actions, H2 2016 21
Number of Products by Stage and Mechanism of Actions, H2 2016 21
Number of Products by Routes of Administration, H2 2016 23
Number of Products by Stage and Routes of Administration, H2 2016 23
Number of Products by Molecule Types, H2 2016 25
Number of Products by Stage and Molecule Type, H2 2016 25

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *